BioCentury
ARTICLE | Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks its FGF21 analog could be superior to other compounds that aim to treat the underlying metabolic causes of NASH

May 17, 2019 9:19 PM UTC

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be superior to others in development.

The company launched last year with a $60 million series A round and two discarded compounds from Teva Pharmaceutical Industries Ltd. to address the absence of marketed drugs to treat non-alcoholic steatohepatitis...